Skip to main content
EXACT Therapeutics AS logo

EXACT Therapeutics AS — Investor Relations & Filings

Ticker · EXTX ISIN · NO0010852213 LEI · 2138006ZE5JAL39AGD55 OL Manufacturing
Open in API
Filings indexed 233 across all filing types
Latest filing 2021-01-20 Regulatory Filings
Country NO Norway
Listing OL EXTX

About EXACT Therapeutics AS

https://www.exact-tx.com/

EXACT Therapeutics AS is a clinical-stage biopharmaceutical company developing its proprietary technology platform, Acoustic Cluster Therapy (ACT®), for targeted therapeutic enhancement. The ACT® platform uses ultrasound to amplify the effect of co-administered drugs, with a primary focus on oncology. Its biomechanical mode of action increases the local uptake of therapeutics from blood vessels into the surrounding tissue, including across the blood-brain barrier, without requiring drug reformulation. This non-invasive technology is designed to be compatible with standard ultrasound systems. The company's pipeline includes the ENACT study, a Phase 2 trial evaluating ACT® in patients with locally advanced pancreatic cancer, following the completion of the ACTIVATE Phase 1 study in patients with liver metastases.

Recent filings

Filing Released Lang Actions
EXACT THERAPEUTICS ANNOUNCES INNOVATIVE PROBE DEVELOPMENT COLLABORATION WITH GE HEALTHCARE
Regulatory Filings Classification · 100% confidence The document is a press release announcing a collaboration between EXACT THERAPEUTICS AS and GE HEALTHCARE regarding the development of an ultrasound probe for use with Acoustic Cluster Therapy (ACT®). This type of announcement, detailing strategic partnerships, technology development, and clinical trial updates, is typically classified as a general corporate announcement or news release. Since there is no specific category for 'Strategic Partnership Announcement' and the document is short (2321 chars) and serves to inform the market of a significant event rather than being a formal regulatory report (like 10-K, IR, or ER), the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements that don't fit elsewhere, or potentially Investor Presentation (IP) if it were a slide deck, but here it reads like a news release. Given the options, RNS is the best fit for a general, non-financial-specific corporate news announcement.
2021-01-20 English
Financial calendar
Report Publication Announcement Classification · 98% confidence The document is titled 'Financial calendar' and lists scheduled dates for future corporate events, specifically mentioning the 'Annual Report' and 'Annual General Meeting' dates for 2020 and 2021, along with a 'Half-yearly Report' date. This is not the report itself, nor is it a specific announcement of a result (like ER or DIV). It is a forward-looking schedule of corporate events and reporting dates. This type of forward-looking schedule or calendar does not fit neatly into the defined categories (like 10-K, ER, AGM-R, etc.). Therefore, the most appropriate fallback category is Regulatory Filings (RNS), as it is a general corporate disclosure required under continuing obligations.
2020-12-23 English
Primary Insider Notification
Director's Dealing Classification · 98% confidence The document is titled 'Primary Insider Notification' and details a share transfer between entities associated with the CFO and a Board member of EXACT Therapeutics AS. This type of transaction report, involving personal share dealings by directors and executives (insiders), directly corresponds to the definition of 'Director's Dealing'. The filing type code for this is DIRS.
2020-10-28 English
EXACT-Therapeutics AS: Primary Insider Notification
Director's Dealing Classification · 98% confidence The document is titled 'EXACT-Therapeutics AS: Primary Insider Notification' and details a share transfer between entities fully owned by the CFO and a Board member. This type of transaction, involving personal share dealings by directors and executives, directly corresponds to the definition of Director's Dealing (DIRS). The document is short and contains specific insider transaction details, not a general regulatory announcement or a full financial report.
2020-09-23 English
EXACT-Therapeutics AS: Primary Insider Notification
Director's Dealing Classification · 98% confidence The document is titled "EXACT-Therapeutics AS: Primary Insider Notification" and details a share transaction (sale of 80,645 shares) by a primary insider, Dr. Per Sontum. It explicitly mentions the number of shares controlled after the transaction and the percentage ownership (6.4%). This type of filing, reporting personal share transactions by directors and executives, directly corresponds to the definition of Director's Dealing (DIRS). The document length is short (2539 chars), but its content is a direct report of the transaction, not an announcement of a report, making DIRS the most accurate classification.
2020-09-18 English
EXACT THERAPEUTICS RESTARTS PHASE I ACTIVATE STUDY
Regulatory Filings Classification · 95% confidence The document is a press release announcing the restart of patient enrollment in a Phase I clinical study (ACTIVATE) for a company named EXACT THERAPEUTICS AS. It details the study's purpose, current enrollment status, and includes quotes from the CEO and a principal investigator. This type of announcement, focusing on clinical trial progress and operational updates rather than comprehensive financial results (like 10-K or ER) or management changes (MANG), is best classified as a general regulatory announcement or news release. Since there is no specific category for clinical trial updates, and it is not a formal financial report, it falls under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous official company announcements.
2020-09-03 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.